Top Qs
Timeline
Chat
Perspective
HL156A
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
HL156A is a derivative of metformin and a potent oxidative phosphorylation inhibitor and AMP-activated protein kinase activating biguanide.[1][2] Certain types of cancer cells requires oxidative phosphorylation to survive. By targeting it, HL156A might help in improving anticancer therapy.[3] It is more potent than acadesine or metformin at activating AMP-activated protein kinase.[2] It is synthesized by Hanall Biopharma.[4]
 | This article may be too technical for most readers to understand. (May 2021) |
Remove ads
Medical uses
It is in phase 1 trial in patients with advanced solid tumor and lymphoma.[5][1]
Pharmacology
 | This section is missing information about how the AMP-activated protein kinase effect translates to oxidative phosphorylation inhibition; whether these extra effects are downstream or independent of AMPK; whether a direct target is known (AMPK is not the direct target for metformin). (July 2022) |
Apart from AMP-activated protein kinase activation, it also inhibits expression and activation of insulin-like growth factor-1, protein kinase B, mammalian target of rapamycin (mTOR), and extracellular signal-regulated kinases.[6][7]
Remove ads
Research
It is researched in multiple conditions like liver and renal fibrosis,[2][8] cancer[6][9] and drug resistance in cancer.[7] HL176OUT04, a drug with similar pharmacology, has been also developed.[10]
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads